These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 29069844)
1. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials. Jang HJ; Kim BJ; Kim JH; Kim HS Oncotarget; 2017 Sep; 8(42):73009-73016. PubMed ID: 29069844 [TBL] [Abstract][Full Text] [Related]
2. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis. Hu W; Xu WS; Liao XF; He HJ Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763 [TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials. Liang RF; Zheng LL Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. Baraniskin A; Buchberger B; Pox C; Graeven U; Holch JW; Schmiegel W; Heinemann V Eur J Cancer; 2019 Jan; 106():37-44. PubMed ID: 30476731 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a meta-analysis. Wang M; Zheng X; Ruan X; Ye B; Cai L; Lin F; Tu J; Jiang F; Li S Chin Med J (Engl); 2014; 127(3):538-46. PubMed ID: 24451964 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer. Ruan WC; Che YP; Ding L; Li HF Comb Chem High Throughput Screen; 2018; 21(10):718-724. PubMed ID: 30663563 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis. Zhou M; Yu P; Qu J; Chen Y; Zhou Y; Fu L; Zhang J Cell Physiol Biochem; 2016; 40(1-2):361-369. PubMed ID: 27866194 [TBL] [Abstract][Full Text] [Related]
8. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer]. Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924 [TBL] [Abstract][Full Text] [Related]
9. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. Artaç M; Coşkun HŞ; Dane F; Karabulut B; Korkmaz L; Karaağaç M; Çabuk D; Karabulut S; Faruk Aykan N; Doruk H; Avcı N; Turhal NS J Gastrointest Cancer; 2016 Sep; 47(3):264-72. PubMed ID: 27126591 [TBL] [Abstract][Full Text] [Related]
10. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis. Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of adding bevacizumab in the first-line chemotherapy of metastatic colorectal cancer: evidence from seven randomized clinical trials. Chen YX; Yang Q; Kuang JJ; Chen SY; Wei Y; Jiang ZM; Xie DR Gastroenterol Res Pract; 2014; 2014():594930. PubMed ID: 24971091 [TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis. Lin Z; Yang Y; Huang Y; Liang J; Lu F; Lao X Mol Clin Oncol; 2015 Jul; 3(4):959-967. PubMed ID: 26171215 [TBL] [Abstract][Full Text] [Related]
13. The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study. Hammerman A; Greenberg-Dotan S; Battat E; Feldhamer I; Bitterman H; Brenner B Acta Oncol; 2015 Feb; 54(2):164-70. PubMed ID: 25350524 [TBL] [Abstract][Full Text] [Related]
14. Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis. Stein A; Schwenke C; Folprecht G; Arnold D Clin Colorectal Cancer; 2016 Jun; 15(2):e29-39. PubMed ID: 26781523 [TBL] [Abstract][Full Text] [Related]
15. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis. Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322 [TBL] [Abstract][Full Text] [Related]
16. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer. Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date. Zhang G; Zhou X; Lin C Int J Clin Exp Med; 2015; 8(1):1434-45. PubMed ID: 25785152 [TBL] [Abstract][Full Text] [Related]
18. Optimizing the efficacy of first-line chemotherapy plus bevacizumab in metastatic colorectal cancer: analysis of multiple methods. Li S; Chi P BioDrugs; 2011 Feb; 25(1):43-50. PubMed ID: 21080747 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis. Ma H; Wu X; Tao M; Tang N; Li Y; Zhang X; Zhou Q Medicine (Baltimore); 2019 Dec; 98(50):e18227. PubMed ID: 31852082 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials. Sidhu R; Rong A; Dahlberg S Clin Cancer Res; 2013 Mar; 19(5):969-76. PubMed ID: 23303214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]